Rare Disease Report sat down with AdAlta CEO Sam Cobb to discuss the impetus for the redesign of AD-214, and what it means for those in the idopathic pulmonary fibrosis.
Sam Cobb
Advertisement
Articles by Sam Cobb
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on HCPLive
1
Moving the Needle in Medicine: Mentorship, Medicine, and the Making of an Innovator, With Jim Januzzi, MD
2
Inhaled Treprostinil Improves IPF Outcomes in Phase 3 TETON-1 Trial
3
What We Still Don't Know: Gaps, Phototherapy, and the Future of Pediatric Eczema Care
4
6 Gastroenterology Headlines You Missed in May 2026
5